Ovarian cancer: Can proteomics give new insights for therapy and diagnosis?

International Journal of Molecular Sciences

Volumn 14, Issue 4, 2013, Pages 8271-8290

  Toss, Angela ^a   De Matteis, Elisabetta ^a   Rossi, Elena ^a   Casa, Lara Della ^a   Iannone, Anna ^a   Federico, Massimo ^a   Cortesi, Laura ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Biomarker; OVA1; Ovarian cancer; Proteomic; Therapy

Indexed keywords

GEFITINIB; HISTONE DEACETYLASE INHIBITOR; OLAPARIB; RETASPIMYCIN; THIOL SPECIFIC ANTIOXIDANT; TUMOR MARKER; UNCLASSIFIED DRUG; PROTEOME; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; DISEASE MARKER; DRUG MECHANISM; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUTATIONAL ANALYSIS; OVARY CANCER; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL GEL ELECTROPHORESIS; FEMALE; GENETICS; MASS SPECTROMETRY; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PROCEDURES; TRENDS;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MASS SPECTROMETRY; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84877069374     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14048271     Document Type: Review

References (72)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
2. Siegel, R.; DeSantis, C.; Virgo, K.; Stein, K.; Mariotto, A.; Smith, T.; Cooper, D.; Gansler, T.; Lerro, C.; Fedewa, S.; et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
3. Lee, J.M.; Kohn, E.C. Proteomics as a guiding tool for more effective personalized therapy. Ann. Oncol. 2010, 21, vii205-vii210.
4. Hays, J.L.; Kim, G.; Giuroiu, I.; Kohn, E.C. Proteomics and ovarian cancer: Integrating proteomics information into clinical care. J. Proteomics 2010, 73, 1864-1872.
5. Bast, R.C., Jr.; Hennessy, B.; Mills, G.B. The biology of ovarian cancer: New opportunities for translation. Nat. Rev. Cancer 2009, 9, 415-428.
6. Marquez, R.T.; Baggerly, K.A.; Patterson, A.P.; Liu, J.; Broaddus, R.; Frumovitz, M.; Atkinson, E.N.; Smith, D.I.; Hartmann, L.; Fishman, D. et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 2005, 11, 6116-6126.
7. Cheng, W.; Liu, J.; Yoshida, H.; Rosen, D.; Naora, H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat. Med. 2005, 11, 531-537.
8. Kurman, R.J.; Shih, I.M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum. Pathol. 2011, 42, 918-931.
9. Liliac, L.; Amalinei, C.; Balan, R.; Grigoras, A.; Caruntu, I.D. Ovarian cancer: Insights into genetics and pathogeny. Histol. Histopathol. 2012, 27, 707-719.
10. Kurman, R.J.; Shih, I.M. Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 2008, 27, 151-160.
11. Havrilesky, L.; Darcy, K.M.; Hamdan, H.; Priore, R.L.; Leon, J.; Bell, J.; Berchuck, A. Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2003, 21, 3814-3825.
12. Longuespée, R.; Boyon, C.; Desmons, A.; Vinatier, D.; Leblanc, E.; Farré, I.; Wisztorski, M.; Ly, K.; D'Anjou, F.Day, R.et al; Ovarian cancer molecular pathology. Cancer Metastasis Rev. 2012, 31, 713-732.
13. Watson, P.Bützow, R.Lynch, H.T.Mecklin, J.P.Järvinen, H.J.Vasen, H.F.Madlensky, L.Fidalgo, P.Bernstein, I. International Collaborative Group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol. Oncol. 2001, 82, 223-228.
14. Walsh, T.; Casadei, S.; Coats, K.H.; Swisher, E.; Stray, S.M.; Higgins, J.; Roach, K.C.; Mandell, J.; Lee, M.K.; Ciernikova, S. et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295, 1379-1388.
15. Casadei, S.; Norquist, B.M.; Walsh, T.; Stray, S.; Mandell, J.B.; Lee, M.K.; Stamatoyannopoulos, J.A.; King, M.C. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011, 71, 2222-2229.
16. Engel, N.J.; Gordon, P.; Thull, D.L.; Dudley, B.; Herstine, J.; Jankowitz, R.C.; Zorn, K.K. A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer. Fam. Cancer 2012, 11, 419-427.
17. Rubin, S.C.; Blackwood, M.A.; Bandera, C.; Behbakht, K.; Benjamin, I.; Rebbeck, T.R.; Boyd, J. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. Am. J. Obstet. Gynecol. 1998, 178, 670-677.
18. Kolch, W.; Mischak, H.; Pitt, A.R. The molecular make-up of a tumour: Proteomics in cancer research. Clin. Sci. (Lond.) 2005, 108, 369-383.
19. Zhang, B.; Barekati, Z.; Kohler, C.; Radpour, R.; Asadollahi, R.; Holzgreve, W.; Zhong, X.Y. Proteomics and biomarkers for ovarian cancer diagnosis. Ann. Clin. Lab. Sci. 2010, 40, 218-225.
20. Rogowska-Wrzesinska, A.; Le Bihan, M.C.; Thaysen-Andersen, M.; Roepstorff, P.J. 2D gels still have a niche in proteomics. J. Proteomics 2013, in press.
21. Hood, B.L.; Malehorn, D.E.; Conrads, T.P.; Bigbee, W.L. Serum proteomics using mass spectrometry. Methods Mol. Biol. 2009, 520, 107-128.
22. Altelaar, A.F.; Munoz, J.; Heck, A.J. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat. Rev. Genet. 2013, 14, 35-48.
23. Mallick, P.; Kuster, B. Proteomics: A pragmatic perspective. Nat. Biotechnol. 2010, 28, 695-709.
24. Tessitore, A.; Gaggiano, A.; Cicciarelli, G.; Verzella, D.; Capece, D.; Fischietti, M.; Zazzeroni, F.; Alesse, E. Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int. J. Proteomics 2013, 2013, 125858.
25. McDonnell, L.A.; Heeren, R.M. Imaging mass spectrometry. Mass Spectrom. Rev. 2007, 26, 606-643.
26. Gagnon, H.; Franck, J.; Wisztorski, M.; Day, R.; Fournier, I.; Salzet, M. Targeted mass spectrometry imaging: Specific targeting mass spectrometry imaging technologies from history to perspective. Prog. Histochem. Cytochem. 2012, 47, 133-174.
27. Boja, E.S.; Rodriguez, H. Mass spectrometry-based targeted quantitative proteomics: Achieving sensitive and reproducible detection of proteins. Proteomics 2012, 12, 1093-1110.
28. Zhang, B.; Cai, F.F.; Zhong, X.Y. An overview of biomarkers for the ovarian cancer diagnosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 158, 119-123.
29. Ardekani, A.M.; Akhondi, M.M.; Sadeghi, M.R. Application of genomic and proteomic technologies to early detection of cancer. Arch. Iran. Med. 2008, 11, 427-434.
30. Sheehan, K.M.; Calvert, V.S.; Kay, E.W.; Lu, Y.; Fishman, D.; Espina, V.; Aquino, J.; Speer, R.; Araujo, R.MillsG.B.et al; Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell Proteomics 2005, 4, 346-355.
31. Mechref, Y.; Hu, Y.; Garcia, A.; Hussein, A. Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis 2012, 33, 1755-1767.
32. Mechref, Y.; Hu, Y.; Garcia, A.; Zhou, S.; Desantos-Garcia, J.L.; Hussein, A. Defining putative glycan cancer biomarkers by MS. Bioanalysis 2012, 4, 2457-2469.
33. Abbott, K.L.; Lim, J.M.; Wells, L.; Benigno, B.B.; McDonald, J.F.; Pierce, M. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics 2010, 10, 470-481.
34. Shetty, V.; Hafner, J.; Shah, P.; Nickens, Z.; Philip, R. Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clin. Proteomics 2012, 9, 10.
35. Kuzmanov, U.; Musrap, N.; Kosanam, H.; Smith, C.R.; Batruch, I.; Dimitromanolakis, A.; Diamandis, E.P. Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. Clin. Chem. Lab. Med. 2012, 8, 1-10.
36. Rogne, M.; TaskénK. Cell signalling analyses in the functional genomics era. New Biotechnol. 2013, in press.
37. Fíla, J.; Honys, D. Enrichment techniques employed in phosphoproteomics. Amino Acids 2012, 43, 1025-1047.
38. Harsha, H.C.; Pandey, A. Phosphoproteomics in cancer. Mol. Oncol. 2010, 4, 482-495.
39. Dann, R.B.; Kelley, J.L.; Zorn, K.K. Strategies for ovarian cancer prevention. Obstet. Gynecol. Clin. N. Am. 2007, 34, 667-686.
40. Petricoin, E.F., III; Ardekani, A.M.; Hitt, B.A.; Levine, P.J.; Fusaro, V.A.; Steinberg, S.M.; Mills, G.B.; Simone, C.; Fishman, D.A.; Kohn, E.C. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
41. Nossov, V.; Amneus, M.; Su, F.; Lang, J.; Janco, J.M.; Reddy, S.T.; Farias-Eisner, R. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am. J. Obstet. Gynecol. 2008, 199, 215-223.
42. Cortesi, L.; Rossi, E.; Della Casa, L.; Barchetti, A.; Nicoli, A.; Piana, S.; Abrate, M.; La Sala, G.B.; Federico, M.; Iannone, A. Protein expression patterns associated with advanced stage ovarian cancer. Electrophoresis 2011, 32, 1992-2003.
43. Petri, A.L.; Simonsen, A.H.; Yip, T.T.; Hogdall, E.; Fung, E.T.; Lundvall, L.; Hogdall, C. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet. Gynecol. Scand. 2009, 88, 18-26.
44. Li, X.Q.; Zhang, S.L.; Cai, Z.; Zhou, Y.; Ye, T.M.; Chiu, J.F. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett. 2009, 275, 109-116.
45. Jackson, D.; Craven, R.A.; Hutson, R.C.; Graze, I.; Lueth, P.; Tonge, R.P.; Hartley, J.L.; Nickson, J.A.; Rayner, S.J.; Johnston, C. et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin. Cancer Res. 2007, 13, 7370-7379.
46. An, H.J.; Kim, D.S.; Park, Y.K.; Kim, S.K.; Choi, Y.P.; Kang, S.; Ding, B.; Cho, N.H. Comparative proteomics of ovarian epithelial tumors. J. Proteome Res. 2006, 5, 1082-1090.
47. Dieplinger, H.; Ankerst, D.P.; Burges, A.; Lenhard, M.; Lingenhel, A.; Fineder, L.; Buchner, H.; Stieber, P. Afamin and apolipoprotein A-IV: Novel protein markers for ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1127-1133.
48. Aktas, B.; Kasimir-Bauer, S.; Wimberger, P.; Kimmig, R.; Heubner, M. Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer. Anticancer Res. 2013, 33, 329-336.
49. Montagnana, M.; Danese, E.; Giudici, S.; Franchi, M.; Guidi, G.C.; Plebani, M.; Lippi, G. HE4 in ovarian cancer: From discovery to clinical application. Adv. Clin. Chem. 2011, 55, 1-20.
50. Drapkin, R.; von Horsten, H.H.; Lin, Y.; Mok, S.C.; Crum, C.P.; Welch, W.R.; Hecht, J.L. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65, 2162-2169.
51. Azzam, A.Z.; Hashad, D.I.; Kamel, N.A. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: Is it time for a step forward? Arch. Gynecol. Obstet. 2013, in press.
52. Moore, R.G.; McMeekin, D.S.; Brown, A.K.; DiSilvestro, P.; Miller, M.C.; Allard, W.J.; Gajewski, W.; Kurman, R.; Bast, R.C., Jr.; Skates, S.J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009, 112, 40-46.
53. Van Gorp, T.; Cadron, I.; Despierre, E.; Daemen, A.; Leunen, K.; Amant, F.; Timmerman, D.; de Moor, B.; Vergote, I. HE4 and CA125 as a diagnostic test in ovarian cancer: Prospective validation of the Risk of Ovarian Malignancy Algorithm. Br. J. Cancer 2011, 104, 863-870.
54. Gorelik, E.; Landsittel, D.P.; Marrangoni, A.M.; Modugno, F.; Velikokhatnaya, L.; Winans, M.T.; Bigbee, W.L.; Herberman, R.B.; Lokshin, A.E. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 981-987.
55. Mor, G.; Visintin, I.; Lai, Y.; Zhao, H.; Schwartz, P.; Rutherford, T.; Yue, L.; Bray-Ward, P.; Ward, D.C. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 7677-7682.
56. Kim, K.; Visintin, I.; Alvero, A.B.; Mor, G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin. Lab. Med. 2009, 29, 47-55.
57. Sarojini, S.; Tamir, A.; Lim, H.; Li, S.; Zhang, S.; Goy, A.; Pecora, A.; Suh, K.S. Early detection biomarkers for ovarian cancer. J. Oncol. 2012, 2012, 709049.
58. Lim, R.; Lappas, M.; Riley, C.; Borregaard, N.; Moller, H.J.; Ahmed, N.; Rice, G.E. Investigation of human cationic antimicrobial protein-18 (hCAP-18), lactoferrin and CD163 as potential biomarkers for ovarian cancer. J. Ovarian Res. 2013, 6, 5.
59. Moore, L.E.; Pfeiffer, R.M.; Zhang, Z.; Lu, K.H.; Fung, E.T.; Bast, R.C., Jr. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012, 118, 191-100.
60. Zhang, Y.; Xu, B.; Liu, Y.; Yao, H.; Lu, N.; Li, B.; Gao, J.; Guo, S.; Han, N.; Qi, J. et al. The ovarian cancer-derived secretory/releasing proteome: A repertoire of tumor markers. Proteomics 2012, 12, 1883-1891.
61. Polanski, M.; Anderson, N.L. A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights 2007, 1, 1-48.
62. Zhang, Z.; Bast, R.C., Jr.; Yu, Y.; Li, J.; Sokoll, L.J.; Rai, A.J.; Rosenzweig, J.M.; Cameron, B.; Wang, Y.Y.; Meng, X.Y. et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
63. Rai, A.J.; Zhang, Z.; Rosenzweig, J.; Shih, I.M.; Pham, T.; Fung, E.T.; Sokoll, L.J.; Chan, D.W. Proteomic approaches to tumor marker discovery-Identification of biomarkers for ovarian cancer. Arch. Pathol. Med. 2002, 126, 1518-1526.
64. Zhang, Z.; Chan, D.W. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 2995-2999.
65. Fung, E.T. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin. Chem. 2010, 56, 327-329.
66. Zhu, C.S.; Pinsky, P.F.; Cramer, D.W.; Ransohoff, D.F.; Hartge, P.; Pfeiffer, R.M.; Urban, N.; Mor, G.; Bast, R.C., Jr.; Moore, L.E. et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev. Res. (Phila.) 2011, 4, 375-383.
67. Posadas, E.M.; Liel, M.S.; Kwitkowski, V.; Minasian, L.; Godwin, A.K.; Hussain, M.M.; Espina, V.; Wood, B.J.; Steinberg, S.M.; Kohn, E.C. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007, 109, 1323-1330.
68. Posadas, E.M.; Kwitkowski, V.; Kotz, H.L.; Espina, V.; Minasian, L.; Tchabo, N.; Premkumar, A.; Hussain, M.M.; Chang, R.; Steinberg, S.M.; et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: A phase II clinical study with proteomic profiling. Cancer 2007, 110, 309-17.
69. Maloney, A.; Clarke, P.A.; Naaby-Hansen, S.; Stein, R.; Koopman, J.O.; Akpan, A.; Yang, A.; Zvelebil, M.; Cramer, R.; Stimson, L. et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17--demethoxygeldanamycin. Cancer Res. 2007, 67, 3239-3253.
70. Banerjee, S.; Kaye, S.B.; Ashworth, A. Making the best of PARP inhibitors in ovarian cancer. Nat. Rev. Clin. Oncol. 2010, 7, 508-519.
71. Ratner, E.S.; Sartorelli, A.C.; Lin, Z.P. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr. Opin. Oncol. 2012, 24, 564-571.
72. Stefansson, O.A.; Jonasson, J.G.; Johannsson, O.T.; Olafsdottir, K.; Steinarsdottir, M.; Valgeirsdottir, S.; Eyfjord, J.E. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res. 2009, 11, R47.